Follow
Christopher Bowlus
Christopher Bowlus
Verified email at ucdavis.edu - Homepage
Title
Cited by
Cited by
Year
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis
F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ...
New England Journal of Medicine 375 (7), 631-643, 2016
10862016
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
DC Klonoff, JB Buse, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ...
Current medical research and opinion 24 (1), 275-286, 2008
10372008
Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases
KD Lindor, CL Bowlus, J Boyer, C Levy, M Mayo
Hepatology 69 (1), 394-419, 2019
7082019
Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis
TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ...
Gastroenterology 152 (8), 1975-1984. e8, 2017
4642017
Primary biliary cirrhosis
C Selmi, CL Bowlus, ME Gershwin, RL Coppel
The Lancet 377 (9777), 1600-1609, 2011
4392011
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ...
Nature genetics 45 (6), 670-675, 2013
4302013
Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis
RY Lan, C Cheng, ZX Lian, K Tsuneyama, GX Yang, Y Moritoki, ...
Hepatology 43 (4), 729-737, 2006
3622006
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open …
JB Buse, DC Klonoff, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ...
Clinical therapeutics 29 (1), 139-153, 2007
3602007
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
SG Ji, BD Juran, S Mucha, T Folseraas, L Jostins, E Melum, N Kumasaka, ...
Nature genetics 49 (2), 269-273, 2017
3062017
Biliary apotopes and anti‐mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis
A Lleo, CL Bowlus, GX Yang, P Invernizzi, M Podda, J Van de Water, ...
Hepatology 52 (3), 987-998, 2010
2482010
IL‐12/Th1 and IL‐23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy
CY Yang, X Ma, K Tsuneyama, S Huang, T Takahashi, NP Chalasani, ...
Hepatology 59 (5), 1944-1953, 2014
2232014
Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid
M Tsuda, Y Moritoki, ZX Lian, W Zhang, K Yoshida, K Wakabayashi, ...
Hepatology 55 (2), 512-521, 2012
2112012
The diagnosis of primary biliary cirrhosis
CL Bowlus, ME Gershwin
Autoimmunity reviews 13 (4-5), 441-444, 2014
2082014
The nonsteroidal farnesoid X receptor agonist cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis
M Trauner, A Gulamhusein, B Hameed, S Caldwell, ML Shiffman, ...
Hepatology 70 (3), 788-801, 2019
2032019
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis
CA Aoki, CM Roifman, ZX Lian, CL Bowlus, GL Norman, Y Shoenfeld, ...
Journal of autoimmunity 27 (1), 50-53, 2006
1982006
De novo nonalcoholic fatty liver disease after liver transplantation
S Seo, K Maganti, M Khehra, R Ramsamooj, A Tsodikov, C Bowlus, ...
Liver Transplantation 13 (6), 844-847, 2007
1942007
DMT1 gene expression and cadmium absorption in human absorptive enterocytes
J Tallkvist, CL Bowlus, B Lönnerdal
Toxicology letters 122 (2), 171-177, 2001
1812001
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised …
D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ...
The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017
1622017
The geoepidemiology of autoimmune intestinal diseases
I Logan, CL Bowlus
Autoimmunity reviews 9 (5), A372-A378, 2010
1582010
Transforming growth factor β (TGF-β) and autoimmunity
CA Aoki, AT Borchers, M Li, RA Flavell, CL Bowlus, AA Ansari, ...
Autoimmunity reviews 4 (7), 450-459, 2005
1552005
The system can't perform the operation now. Try again later.
Articles 1–20